3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
9
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Melanoma
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
pembrolizumab
126
Cisplatin
48
Cetuximab
46
Nivolumab
36
Carboplatin
33
Paclitaxel
28
Fluorouracil
26
Docetaxel
17
Cyclophosphamide
12
avelumab
11
Radiotherapy
11
cemiplimab
10
atezolizumab
10
durvalumab
9
Ipilimumab
8
spartalizumab
7
fludarabine
7
budigalimab
7
Gemcitabine
7
Capecitabine
7
tremelimumab
6
lenvatinib
6
Pemetrexed
6
130-nm albumin-bound paclitaxel
6
epacadostat
5
Fulvestrant
5
zimberelimab
4
tislelizumab
4
Trastuzumab
4
Oxaliplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Squamous Cell Carcinoma of Head and Neck
×
Immunotherapy
×
Clear all
NCT02609386
2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2
Completed
105 enrolled
17 charts